Hemolytic Disease of the Fetus and Newborn: Cutting Edge Strategies for Diagnosis and Management

Published: Oct. 30, 2020, 4 a.m.

Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Kenneth J. Moise Jr., MD

Hemolytic disease of the fetus and newborn (HDFN) is a rare condition with an estimated 3-80 cases per 100,000 pregnancies in the US every year. HDFN occurs when maternal red blood cells or blood group antibodies cross the placenta during pregnancy and cause fetal red cell destruction. The physiologic consequences of severe anemia in the fetus can lead to edema, ascites, hydrops, heart failure, and even death.

This activity provides strategies for the diagnosis and management of HDFN, including available algorithms for diagnosis and follow-up therapy.